[SOLV] Solventum Thesis 2026: Dental Divestiture Tests Post-3M Spin Healthcare Refocus
Key Takeaways
- Dental Divestiture Strategic Pivot: Selected announced 2024-2025 Dental Solutions segment divestiture process (~$1.2B revenue; selected ~$3-4B+ valuation expected; selected strategic alternatives review post-spin); selected divestiture proceeds redeployment toward Medical Surgical + Health Information Systems + Purification & Filtration core focus; FY2026 catalyst: divestiture closing + selected post-divestiture pure-play healthcare focus.
- Post-3M Spin Transition: April 1, 2024 spin-off from 3M completed (selected $8.2B 3M Healthcare segment separated as Solventum); selected
$8B+ debt assumed from 3M; selected post-spin transition costs ($200-300M); FY2026 catalyst: continued separation completion + selected operating margin expansion + selected capital return resumption post-deleveraging. - Medical Surgical Leadership: Medical Surgical segment ~$4.1B FY2025 (~50% of total); selected surgical solutions (selected ~$2B+ revenue) + advanced wound care (selected ~$1.5B+ post-3M legacy Tegaderm + selected) + sterilization indicators; FY2026 expected Medical Surgical toward $4.2-4.3B (+2-5%) on continued surgical procedure recovery + selected wound care growth.
- Health Information Systems + AI Coding: Health Information Systems ~$1.2B FY2025 (~15% of total); selected clinical documentation + AI-powered coding/CDI (computer-assisted CDI); selected post-2024 hospital revenue cycle automation tailwind + selected AI/ML coding adoption; FY2026 expected HIS toward $1.3-1.4B (+5-10%).
Company Background
Solventum Corporation (NYSE: SOLV) is the leading global healthcare technology firm spun off from 3M Company on April 1, 2024 as the former 3M Healthcare segment ($8.2B revenue baseline). Selected post-spin standalone Solventum operations include selected ~120-year heritage as part of 3M's healthcare portfolio (selected dating to 3M's 1902 founding + selected Riker Laboratories 1962 acquisition + selected various healthcare M&A through ~120-year history). Selected post-spin Solventum independent operations + selected ~$8B+ debt assumed from 3M parent.
Headquartered in Maplewood Minnesota; ~22,000+ employees globally with FY2025 revenue ~$8.2-8.4B (-1 to +2% YoY) generating ~$700-900M net income (~9-11% net margin reflecting selected post-spin transition costs + selected interest expense impact) and ~$4.00-5.00 EPS on ~172M diluted shares.
The company operates four reporting segments: Medical Surgical ~50% of revenue ($4.1B — selected surgical solutions including selected drapes + selected gowns + selected medical adhesives + selected advanced wound care including Tegaderm + Coban + selected sterilization indicators), Dental Solutions ~15% ($1.2B — selected dental restorative + orthodontic; selected announced divestiture process 2024-2025 ~$3-4B+ valuation expected), Health Information Systems ~15% ($1.2B — clinical documentation + AI-powered coding/CDI computer-assisted CDI), and Purification & Filtration ~20% ($1.7B — water + biopharma filtration including selected biopharma single-use filtration + selected industrial water).
CEO Bryan Hanson since April 2023 (~2.5-year tenure pre-spin; selected appointed by 3M to lead spin-off transformation; ex-Zimmer Biomet CEO 2017-March 2023 + ex-Medtronic Global Diabetes + selected various roles 1989-2017 ~30-year Medtronic career). Selected Hanson era characterized by: (i) selected post-2023 spin-off preparation + execution; (ii) selected April 2024 successful spin closing; (iii) selected post-2024 strategic refocus including Dental divestiture process; (iv) selected post-2024 operating margin expansion focus.
Dental Divestiture: $3-4B+ Strategic Pivot
Selected post-2024 Dental Solutions strategic alternatives review represents Solventum's most significant strategic action post-spin. Selected Dental segment revenue ~$1.2B FY2025 (~15% of total) reflects: (i) selected dental restorative materials (selected Filtek + selected); (ii) selected orthodontic (selected Clarity + selected); (iii) selected dental adhesives + cementation; (iv) selected ~50%+ international revenue.
Selected announced 2024-2025 divestiture process targeting ~$3-4B+ valuation reflects: (i) selected non-core dental positioning vs Medical Surgical + Health Information Systems + Purification & Filtration; (ii) selected 3-4x revenue valuation reflecting selected category-leading dental materials brand recognition; (iii) selected potential strategic acquirers including selected Henry Schein + Patterson Companies + selected dental specialty firms + selected private equity. Selected divestiture proceeds expected for: (i) selected debt reduction ($8B+ inherited 3M debt); (ii) selected M&A in core focus areas; (iii) selected potential capital return.
FY2026 catalyst: divestiture closing + selected post-divestiture pure-play healthcare focus + selected $8.2B → ~$7B revenue baseline post-divestiture + selected operating margin improvement.
Material change rule: Dental divestiture below $2.5B valuation OR divestiture process disruption OR major strategic refocus reversal.
Post-3M Spin Transition + Operating Margin
Selected April 1, 2024 spin-off from 3M completed (selected $8.2B 3M Healthcare segment separated as Solventum). Selected post-spin transition costs include: (i) selected ~$200-300M post-spin standalone transition costs (IT separation + corporate function build-out); (ii) selected ~$8B+ inherited 3M debt with ~$300-400M annualized interest expense; (iii) selected post-spin operating margin compression vs 3M legacy ~22-24% segment margin.
FY2026 catalyst: continued separation completion + selected operating margin expansion toward 18-20% adj. operating margin reflecting: (i) selected post-2024 cost savings + IT integration completion; (ii) selected supply chain optimization; (iii) selected portfolio focus benefits; (iv) selected post-Dental divestiture margin uplift.
Medical Surgical + Health Information Systems Leadership
Medical Surgical $4.1B FY2025 ($1.5B+; selected Tegaderm + Coban + selected ~30%+ market share); (iii) selected sterilization indicators. FY2026 expected Medical Surgical toward $4.2-4.3B (+2-5%).50% of total) reflects: (i) selected surgical solutions ($2B+; surgical drapes + gowns + medical adhesives); (ii) selected advanced wound care (
Health Information Systems ~$1.2B FY2025 (~15% of total) reflects: (i) selected clinical documentation (selected 3M 360 Encompass + selected); (ii) selected AI-powered coding/CDI (computer-assisted clinical documentation improvement); (iii) selected post-2024 hospital revenue cycle automation tailwind + selected AI/ML coding adoption. FY2026 expected HIS toward $1.3-1.4B (+5-10%).
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $8.4B | $8.2B | $8.2B | $8.2-8.4B | $7.5-8.0B (post-Dental) |
| Medical Surgical | $4.1B | $4.0B | $4.0B | $4.1B | $4.2-4.3B |
| Dental Solutions | $1.4B | $1.3B | $1.2B | $1.2B | $0 (post-divest) |
| Health Information Systems | $1.1B | $1.1B | $1.1B | $1.2B | $1.3-1.4B |
| Purification & Filtration | $1.7B | $1.7B | $1.7B | $1.7B | $1.7-1.8B |
| Adj. Operating Margin | 23% | 21% | 17% | 17-19% | 18-20% (post-Dental) |
| Adj. EPS | $5.10 | $4.71 | $4.20 | $4.00-5.00 | $4.50-5.50 |
| FCF | $1.3B | $1.0B | $0.5B | $0.5-0.8B | $0.7-1.0B |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $0.20 (post-spin partial) | $1.16-1.32 | $1.20-1.40 |
| Buybacks | $0 | $0 | $0-200M |
| Total Capital Return | $35M | $200-230M | $210-440M |
| Credit Rating | Baa3/BBB- | Baa3/BBB- | Baa3/BBB- |
Market Evaluation
SOLV currently trades at ~14-18x earnings reflecting: (i) selected post-3M spin transition; (ii) selected ~$8B+ inherited 3M debt deleveraging; (iii) selected Dental divestiture optionality; offset by (iv) selected Medical Surgical leadership; (v) selected Health Information Systems AI tailwind; (vi) selected Purification & Filtration biopharma exposure.
Selected peer comparison: Medtronic (MDT ~14-17x P/E diversified medical device), Becton Dickinson (BDX ~17-20x P/E medical device + life sciences), Baxter (BAX ~12-15x P/E medical device + renal), Hologic (HOLX ~15-18x P/E women's health). SOLV valuation reflects post-spin transition discount with selected divestiture optionality.
FY2026 catalysts: (i) Dental divestiture closing; (ii) post-3M separation completion; (iii) operating margin expansion; (iv) capital return resumption. Risks: (i) Dental divestiture below $2.5B; (ii) post-spin transition disruption; (iii) Medical Surgical competitive intensity; (iv) interest rate exposure on $8B+ debt.
Dental Divestiture and Healthcare Refocus
The FY2026 thesis hinges on Solventum's ability to execute Dental Solutions divestiture + complete post-3M separation + sustain Medical Surgical + Health Information Systems + Purification & Filtration core focus. Dental divestiture closing at $3-4B+ valuation enables debt reduction + M&A optionality + potential capital return.
Post-divestiture revenue baseline ~$7B FY2026 (reflecting Dental separation) + adj. operating margin 18-20% (reflecting post-divestiture margin uplift + cost savings completion) + adj. EPS $4.50-5.50 (+10-15%). Capital return resumption post-deleveraging supporting potential ~$1.20-1.40 dividend + selected modest buybacks.
Material risks: (i) Dental divestiture below $2.5B valuation; (ii) post-spin transition disruption; (iii) Medtronic + Becton Dickinson competitive substitution; (iv) interest rate severe exposure.
FY2026-2027 base case: revenue $7.5-8.0B (+0% on Dental separation; reset baseline) + $7.7-8.2B (+3-5%); adj. EPS $4.50-5.50 + $5.00-6.00 (+10-15% growth); operating margin 18-20% + 19-22%; capital return $210-440M + $300-600M with potential dividend growth + buyback resumption. Selected post-3M spin healthcare franchise + selected Dental divestiture optionality + selected operating margin expansion support continued strategic focus through FY2027.